Confluence Investment Management LLC reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 10.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 80,145 shares of the medical instruments supplier’s stock after selling 9,757 shares during the quarter. Confluence Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $14,346,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in the company. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $26,000. Meeder Asset Management Inc. raised its position in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares in the last quarter. Main Street Group LTD acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $29,000. Bell Investment Advisors Inc acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $29,000. Finally, Kelleher Financial Advisors acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $30,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Becton, Dickinson and Company
In other news, EVP Michael Feld sold 165 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 6,906 shares of company stock valued at $1,265,855. Corporate insiders own 0.40% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Analysis on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Down 0.2%
NYSE:BDX traded down $0.32 during trading hours on Thursday, hitting $178.68. 325,117 shares of the stock traded hands, compared to its average volume of 2,514,184. The firm has a 50 day moving average price of $179.78 and a 200 day moving average price of $161.47. The firm has a market cap of $49.23 billion, a price-to-earnings ratio of 53.85, a PEG ratio of 12.82 and a beta of 0.21. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.
BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
- First Watch’s Growth Story Meets a Reality Check
- Down 50% and Climbing Again: 3 AI Stocks Rebuilding After Brutal Pullbacks
- Micron’s Earnings Reveal Why the AI Memory Boom May Last Longer
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
